Azurity Pharmaceuticals, Inc.

Based in the US, Azurity Pharmaceuticals, Inc. focuses on developing and commercializing innovative medicines tailored for underrepresented patient populations, enhancing treatment accessibility through a diverse portfolio of products. Azurity Pharmaceuticals, Inc. specializes in creating specialty pharmaceuticals aimed at underserved patient demographics.

Founded in 1998 in Woburn, US, the company underwent a rebranding when Silvergate Pharmaceuticals, Inc. was acquired by CutisPharma, Inc. in June 2019. Under the leadership of CEOs Amit Patel and Richard Blackburn, Azurity has successfully raised a total of USD 4.

60 mn, culminating in its latest funding round in June 2019. The company has engaged in 5 deals to date, reflecting its strategic approach to growth. Azurity Pharmaceuticals specializes in the development and commercialization of innovative medicines aimed at addressing the needs of overlooked patient populations. Their diversified product portfolio includes over 50 medications across 10 different dosage forms and key therapeutic areas such as cardiovascular health, oncology, immunology, and respiratory conditions.

A notable product in their lineup is Javadin™ (clonidine hydrochloride) oral solution, which is the only FDA-approved immediate-release liquid formulation for treating hypertension in adults, released in October 2025. Azurity's products are marketed in over 50 countries, including the United States, Canada, Hong Kong, Macau, Mainland China, and Singapore, targeting healthcare providers, pharmacies, and hospitals as primary customers, ultimately serving patients who may not have adequate treatment options available to them. Revenue generation for Azurity Pharmaceuticals primarily occurs through the sale of its specialty pharmaceuticals to healthcare providers and distributors. The company engages in direct sales and partnership agreements, such as the exclusive distribution deal with ACA Pharma for Feraheme® (ferumoxytol injection) in the Greater Bay Area and Singapore, enhancing its market reach.

Transactions are typically structured as B2B agreements, with healthcare facilities purchasing medications to treat their patients. Flagship products like Javadin™ and Feraheme® represent key revenue streams, as they fulfill significant treatment needs within their respective therapeutic areas. Sales are supported by a Next-Gen Commercial Model that utilizes data and analytics to optimize market engagement and customer relationships. Azurity Pharmaceuticals plans to further its growth by developing new products, including the upcoming Javadin™ oral solution, expected to enhance treatment options for hypertension in adults.

The company aims to expand its market presence in Asia, specifically targeting regions such as Hong Kong and Mainland China, by 2026. Recent funding will support these strategic initiatives, enhancing its capabilities to meet the needs of diverse patient populations while strengthening its service offerings following the acquisition of Silvergate Pharmaceuticals.